# Lupeng Pharmaceuticals

Source: https://onco.cc/companies/lupeng-pharmaceuticals/  
OnCo record `lupeng-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lupeng Pharmaceuticals is a China-based biotechnology company that leads 4 cancer trials in OnCo, testing the Bcl-2 inhibitor lacutoclax (LP-108) and the BTK inhibitor rocbrutinib (LP-168) in chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse large B-cell lymphoma and follicular lymphoma.

## Summary

Lupeng Pharmaceuticals develops next-generation small-molecule targeted drugs for malignant tumours and autoimmune diseases, focused on haematological cancers and the BTK, Bcl-2 and Bcl-xL pathways. Its site states that rocbrutinib (LP-168) is approved by China's NMPA and that lacutoclax (LP-108) has entered pivotal registration studies. On ClinicalTrials.gov it is the lead sponsor of 4 trials recorded in OnCo: NCT07609823 (phase 2, A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL), NCT07609862 (phase 1/2, A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies), NCT05716087 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma) and NCT07189065 (phase 2, A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: Guangzhou Lupeng Pharmaceutical; 鲁鹏医药
- Tags: ctgov-sponsor
- HQ: Guangzhou
- Type: biotech
- Website: https://www.lupengbio.com/

## Sources

- Official website: https://www.lupengbio.com/
- ClinicalTrials.gov: trials led by Lupeng Pharmaceuticals: https://clinicaltrials.gov/search?lead=Guangzhou%20Lupeng%20Pharmaceutical%20Company%20LTD.

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/), [Rocbrutinib](https://onco.cc/drugs/rocbrutinib/)
- trials: [A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL](https://onco.cc/trials/nct07609823/), [A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies](https://onco.cc/trials/nct07609862/), [A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma](https://onco.cc/trials/nct05716087/), [A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma](https://onco.cc/trials/nct07189065/)

---
JSON: https://onco.cc/api/v1/entities/lupeng-pharmaceuticals.json